Alkermes (ALKS) Commences ARTISTRY-7 Phase 3 Trial of Nemvaleukin Alfa in Patients With Platinum-Resistant Ovarian Cancer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/23/2026

1. USO
2. META
3. NVDA
4. SPY
5. DCOY
6. MSFT
7. VKTX
8. PRGS
9. DGX
10. IONQ

Go back to Alkermes (ALKS) Commences ARTISTRY-7 Phase 3 Trial of Nemvaleukin Alfa in Patients With Platinum-Resistant Ovarian Cancer
ALKERMES (NASDAQ: ALKS) Delayed: 43.29 -0.89 (2.01%)
Previous Close $44.18    52 Week High $80.71 
Open $44.39    52 Week Low $27.14 
Day High $44.53    P/E 333.00 
Day Low $43.08    EPS $0.13 
Volume 2,310,733